Adjuvant therapy in colon cancer: Which treatment in 2005?

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Di Costanzo, Francesco ^a,b   Doni, L ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MAGNESIUM; OXALIPLATIN; PLACEBO; UFT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON SURGERY; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DISTRESS SYNDROME; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT PLANNING; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 30644468862     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi911     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: Survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003; 14: 61-118.
3. Wong JH, Bowles BJ, Bueno R et al. Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Clon Rectum 2002; 45: 1341-1348.
4. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-2919.
5. Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil: The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7: 1447-1456.
6. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
7. Bleeker WA, Mulder NH, Hermans J et al. The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. Ann Oncol 2000; 11: 547-552.
8. Di Costanzo F, Sobrero A, Gasperoni S et al. Adjuvant chemotherapy in the treatment of colon cancer: Randomised multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol 2003; 14: 1365-1372.
9. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775.
10. Haller DG, Catalano PJ, MacDonald JS et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five year final report of INT-0089. Proc Am Soc Clin Oncol 1998; 17: 256a (abstract).
11. O'Connell JM, Laurie JA, Shepherd L et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer. A collaborative trial of the North Central Cancer Treatment Group and The National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1996; 15: 478a (abstract).
12. Kerr DJ, Gray R, McConkey C et al. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non-randomised comparison of weekly versus four-weekly schedules-less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann Oncol 2000; 11: 947-955.
13. Andre T, Colin P, Louvet C et al. Randomised adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: Study design and preliminary safety results. Group d'Etude et de Recherche Clinique en Oncologie Radiotherapies. Semin Oncol 2001; 28 (1 Suppl 1): 35-40.
14. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 1947-2938.
15. André T, Bono C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin ad adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
16. Sargent D, Wieand S, Benedetti J et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc Am Soc Clin Oncol 2004; 23: 246 (Abstr 3502).
17. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C898O3). Proc Am Soc Clin Oncol 2004; 23: 246 (Abstract 3500).
18. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
19. Pazdur R, Douillard J-Y, Skillings JR et al. Multicenter phase III study of 5-florouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 1009a.
20. Wolmark N, Wieland S, Lembersky B, Colangelo L, Smith R, Pazdur R. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. Proc Am Soc Clin Oncol 2004; 23 (Suppl): 14 (Abstr 3508).
21. Cassidy J, Scheithauer W, McKendrick J. Capecitabine (X) versus bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III study. Proc Am Soc Clin Oncol 2004; 23 (Suppl): 14 (Abstr 3509).
22. Sakamoto J, Ohashi Y, Hamada C et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22(3): 484-492.
23. Benson AB III, Schrag D, Somerfeld MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419.
24. Zaniboni A, Labianca R Gruppo Italiano per to Studio e la Cura dei Tumori del Digerente: Adjuvant therapyAfor stage II colon cancer: an elephant in the living room? Ann Oncol 2004; 15: 1310-1318.
25. Jansen SJ, otten W, Stiggelbout AM. Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 2004; 22: 3181-3190.
26. Lenz HG, Mayer RJ, Gold PJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 23: 248 (Abstr 3510).
27. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208. (Epub 2004 Mar 01).
28. Cunningham D, Humblet Y, Siena S et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 252 (Abstr 1012).
29. Tabernero JM, Van Cutsem E, Sastre J et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/ folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2004; 23: 248 (Abstr 3512).
30. Rougier P, Raoul JL, Van Laethem JL et al. Cetuximab +FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004; 23: 248 (Abstr 3513).
31. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
32. Kabbinavar FF, Schulz J, McLeod M et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 2004; 23: 249 (Abstr 3516).
33. Chen HX, Mooney M, Boron M et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). Proc Am Soc Clin Oncol 2004; 23: 249 (Abstr 3515).